HOW does MIS-C differ from Kawasaki disease, KD, shock, and TSS
3
Can MIS-C be distinguished from other infectious and inflammatory diseases ?
4
Clinical features conclusions
5
What is the relationship of MISC to COVID 19 and SARS Cov2?
6
Possible mechanism for acquired immunity mediating inflammation and organ damage ??
7
When Should Immunomodulatory Treatments Be Started for MIS-C?
8
Do All MIS-C Patients Need Treatment?
9
Treatment For MIS-C Derived From Kawasaki Disease Management
10
Which Patients Need Anticoagulation?
11
Should Therapy Change If Enlarging Coronary Aneurysm?
12
How Should Management Change in Resource-limited Environments?
13
Does Sequence of Treatment Matter?
14
How Can Biomarkers (D-dimer, fibrinogen) Help Make Anticoagulation Decisions?
Description:
Explore the latest insights on Multisystem Inflammatory Syndrome in Children (MIS-C) related to COVID-19 in this World Shared Practice Forum video from the International PICU COVID-19 Collaborative. Gain valuable knowledge from Dr. Michael Levin's discussion on new MIS-C literature and participate in an expert panel discussion with members of the American College of Rheumatology Task Force on MIS-C. Learn about global trends in COVID-19 treatments, understand the nuances of MIS-C based on recent research, and discover current clinical practice guidance for managing pediatric patients with MIS-C. Delve into topics such as distinguishing MIS-C from Kawasaki disease and other inflammatory conditions, the relationship between MIS-C and SARS-CoV-2, immunomodulatory treatment strategies, anticoagulation decisions, and management considerations in resource-limited environments. Enhance your understanding of this critical pediatric condition and its treatment approaches through this comprehensive 47-minute presentation.
Read more